Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492954 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
A Phase 1 study of Osteosarcoma and Pulmonary Recurrence of Osteosarcoma, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06492954: Recruiting Phase 1 study of Osteosarcoma and Pulmonary Recurrence of Osteosarcoma, sponsored by Emory University.
NCT06492954 is a Phase 1 study of Osteosarcoma and Pulmonary Recurrence of Osteosarcoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 12 participants, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06492954, a Phase 1 study of Osteosarcoma and Pulmonary Recurrence of Osteosarcoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma
Primary Outcome
If 6 participants have been enrolled and evaluated, and only 0 or 1 have experienced a DLT, the next participant will be enrolled at Dose Level 2
Conditions Studied
Interventions
- DRUG Atezolizumab
- PROCEDURE Surgical Resection
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Georgia
- Chilldren's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06492954 shows while recruiting
NCT06492954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT06492954 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06492954 about?
NCT06492954 is a clinical study titled "Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma". This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma
What is the current status of trial NCT06492954?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2027-06.
What conditions does trial NCT06492954 study?
This clinical trial studies the following conditions: Osteosarcoma, Pulmonary Recurrence of Osteosarcoma.
What interventions are being tested in trial NCT06492954?
The interventions under investigation include: Atezolizumab (DRUG), Surgical Resection (PROCEDURE), Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT06492954?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492954 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06492954's enrollment target sits among peer trials
12 42nd of 46 higher than 4 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia